Reviva Pharmaceuticals Holdings, Inc. RVPH 深 沪
已收盘 02-06 16:00:00 美东时间
0.2865
+0.032
+12.35%
华盛通- 最 高0.3069
- 今 开0.2598
- 成交量 354.09万股
- 最 低 0.2576
- 昨 收 0.255
- 总市值 3347.75万
- 52周最高 1.88
- 市盈率 静 --
- 换手率 3.03%
- 52周最低 0.25
- 委 比 58.33%
- 总股本 1.17亿
- 历史最高 15.10
- 量 比 1.88
- 振 幅 19.33%
- 历史最低 0.00
- 每 手 1
- 风险率 0.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Reviva Pharmaceuticals Publishes Data From RECOVER Phase 3 Clinical Study Of Brilaroxazine For Treatment Of Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system
01-08 21:02
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
Reviva Pharmaceuticals Provides Update, Written Feedback From FDA Pre-NDA Meeting, Includes A Recommendation To Conduct A Second Phase 3 Trial To Generate Additional Efficacy And Safety Data Prior To NDA Submission Of Brilaroxazine For The Treatment Of Schizophrenia; Initiation Of RECOVER-2 Registrational Trial Planned In H1 2026
Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of
2025-12-23 21:12
Reviva Pharmaceuticals GAAP EPS of -$0.06
Reviva Pharmaceuticals press release (RVPH): Q3 GAAP EPS of -$0.06. As of September 30, 2025, the Company’s cash and cash equivalents totaled approximately $13.2 million compared to approximately $13....
2025-11-14 05:59
Reviva Pharmaceuticals Q3 EPS $(0.06) Beats $(0.10) Estimate
Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.10) by 38.78 percent. This is a 76 percent increase over losses of $(0.25) per share
2025-11-14 05:34
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis
Reviva Pharmaceuticals获得欧洲专利，覆盖brilaroxazine治疗肺纤维化，包括特发性肺纤维化，全球市场已有类似专利。药物独特机制针对5-羟色胺信号失调，已获FDA孤儿药认定。临床数据显示良好耐受性，拟扩展至其他高价值适应症。
2025-11-10 13:00
Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference
Reviva Pharmaceuticals Holdings, Inc., a late-stage biopharmaceutical company, announced that its CEO, Laxminarayan Bhat, Ph.D., will participate in the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, in New York City. The conference will feature over 60 companies and 500 investors across high-growth sectors. Reviva focuses on developing therapies for CNS, inflammatory, and cardiometabolic diseases, with a pipeli...
2025-10-29 12:00
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
2025-10-29 09:25
Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
Reviva Pharmaceuticals Holdings, Inc. announced that negative symptom data for brilaroxazine from the Phase 3 RECOVER trial and a long-term open-label extension trial in schizophrenia patients will be presented at the CNS Summit 2025 in Boston. The poster, titled "Brilaroxazine Treatment Effect on Negative Symptoms in Schizophrenia: RECOVER Trial in Acute and Stable Patients Over 1 Year," will be displayed on November 3rd and 4th. Abstract detail...
2025-10-28 12:00
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
2025-10-28 10:08
